Get the latest tech news
Dimension raises $500M second fund for investing at the intersection of tech and life sciences
Many VCs, particularly newer firms, readily admit that 2024 has been a challenging year for raising fresh capital. Dimension Capital, a two-year-old
Dimension’s appeal is its unique focus on investing at the nexus of life sciences and technology, an area that has gained popularity in recent years as the promise of drug discovery with artificial intelligence (alongside a bigger push to build AI into a more clinical applications) seems closer than ever. The firm has also backed Enveda Biosciences, a biotech that uses AI to develop medicines from natural compounds, which raised a$130 million Series C last month. “They’re machine learning practitioners, AI engineers, hardware roboticists that are intermingled and symbiotically working together with chemists and biologists to do the drug discovery.”
Or read this on TechCrunch
